IDXX · 8-K · 20260804PR090033

Guidance / Outlook

IDEXX LABORATORIES INC /DE · 2026-08-04 · Importance 85 · Surprise 76

IDEXX narrowed its 2026 revenue guidance to $4,700 million-$4,745 million, raising the midpoint by $5 million and forecasting reported growth of 9.1%-10.3% and organic growth of 8.5%-9.7%. CAG Diagnostics recurring revenue growth is projected at 10.1%-11.3% reported and 9.5%-10.7% organic. The company increased its full-year operating margin outlook to 32.3%-32.5% and EPS outlook to $14.69-$14.94, while continuing investments in commercial capabilities and innovation. Projected 2026 capital expenditures remain approximately $180 million.